Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)

NCT ID: NCT01092091

Last Updated: 2012-03-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2012-02-29

Brief Summary

The purpose of this study is to determine whether recombinant human arginase (PEG-BCT-100) is safe and effective in the treatment of advanced hepatocellular carcinoma (HCC).

Detailed Description

The primary objectives of this study are:

• To evaluate any objective tumor responses to PEG-BCT-100 in HCC patients receiving weekly doses of PEG-BCT-100 alone.
• To perform PK and PD analysis
• To measure Quality of Life of the patients

Secondary objectives of this study are:

• To define any toxicity associated with the metabolic and cellular alterations of ADD relative to dose and PK of PEG-BCT-100 (rhArgIpeg5000).
• To confirm the safety and anti-tumor activity of PEG-BCT-100 at the preferred dose (1600U/kg) in 50 patients (at least 18 evaluable subjects) with advanced HCC.
• To measure duration of response including Overall Survival and Time to Progression analysis

Conditions

Neoplasm; Hepatocellular Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

PEG-BCT-100

Pegylated Recombinant Human Arginase I

Group Type: EXPERIMENTAL

Pegylated Recombinant Human Arginase I

Intervention Type: BIOLOGICAL

Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg

Interventions

Pegylated Recombinant Human Arginase I

Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg

Intervention Type: BIOLOGICAL

Other Intervention Names

PEG-BCT-100

Eligibility Criteria

Inclusion Criteria

• Confirmed diagnosis of HCC according to the European Association for the Study of the Liver criteria
• Known underlying HCC etiology specified by hepatitis B, hepatitis C, post alcoholic cirrhosis, or other
• HCC lesion(s) which are not resectable and which are measurable by C-T scan
• Progression of or non-response of HCC lesions after treatments which are considered best standard of care - surgical resection, radiofrequency ablation, chemoembolization
• No cancer treatment or surgery within the prior 4 weeks, either chemotherapy, targeted biologic or enzymes, either approved or investigational;
• Males or females from 18 to 75 years-old, inclusive;
• Ability and willingness to provide written informed consent;
• Karnofsky performance status of 80% or above and expected survival of more than 12 weeks; and,
• Negative urine pregnancy test, if female, and willingness to use an effective method of contraception during the entire study period
• No cognitive impairment
• Ability to understand and read Chinese

Exclusion Criteria

• Advancing liver failure indicated by uncontrolled ascites, pleural effusions, encephalopathy, or a Child-Pugh score of C
• Significant hepatic, renal or bone marrow dysfunction indicated by total bilirubin >40 µmol/L, evidence of bile duct obstruction, serum albumin <30 g/L, serum SGOT >5 x upper limit of normal, ANC <1.0 x 10^9/L, platelets <100 x 10^9/L, or INR >2.0
• Significant cardiac or pulmonary disease defined by New York Heart Association (NYHA) Class III or IV, VEF <50% by echo or MUGA, or a history of myocardial infarction within the past 6 months, significant unstable arrhythmia or evidence of ischemia on ECG
• Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Significant active infection including HIV requiring oral or parenteral anti-infective therapies;
• Use of investigational drug(s) within 4 weeks of enrollment; or,
• Prior treatment with arginine depleting agent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The University of Hong Kong

OTHER

Sponsor Role: collaborator

Chinese University of Hong Kong

OTHER

Sponsor Role: collaborator

Bio-Cancer Treatment International Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ronnie TP Poon, Prof

Role: PRINCIPAL_INVESTIGATOR

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong

Locations

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong

Hong Kong, , Hong Kong

Countries

Hong Kong

References

Chan SL, Cheng PNM, Liu AM, Chan LL, Li L, Chu CM, Chong CCN, Lau YM, Yeo W, Ng KKC, Yu SCH, Mok TSK, Chan AWH. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. Invest New Drugs. 2021 Oct;39(5):1375-1382. doi: 10.1007/s10637-021-01111-8. Epub 2021 Apr 15.

Reference Type: DERIVED

PMID: 33856599 (View on PubMed)

Related Links

http://www.hkclinicaltrials.com/

HKCTR-503

Other Identifiers

PR/CT0299/2009

Identifier Type: OTHER

Identifier Source: secondary_id

HKCTR-503C

Identifier Type: -

Identifier Source: org_study_id